EWTX
vs
S&P 500
EWTX
S&P 500
Over the past 12 months, EWTX has outperformed S&P 500, delivering a return of +18% compared to the S&P 500's +15% growth.
Stocks Performance
EWTX vs S&P 500
Performance Gap
EWTX vs S&P 500
Performance By Year
EWTX vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Edgewise Therapeutics Inc
Glance View
Edgewise Therapeutics Inc. is a biopharmaceutical company that has carved its niche by focusing intently on developing treatments for rare muscle disorders. Founded with the vision of addressing the unmet needs within the realm of muscular dystrophies and other rare myopathies, Edgewise aims to combat these challenges through precision medicine. Its unique approach lies in leveraging its proprietary drug discovery platform to identify and develop small molecule therapies that target the underlying causes of these muscle disorders. By honing in on the mechanistic roots of muscle dysfunction, Edgewise aspires to improve the quality of life for patients who often have limited treatment options available. The company generates revenue primarily through the successful development and potential commercialization of its therapies. As with many biopharmaceutical entities, the cornerstone of Edgewise's financial strategy is to push its drug candidates through the clinical trial phases efficiently, demonstrating safety and efficacy to obtain regulatory approval. Partnerships, collaborations, and licensing agreements often play a critical role in supplementing its revenue stream, enabling Edgewise to leverage additional resources and expertise. By addressing the therapeutic gaps in rare muscle disorders with promising candidates that have the potential to be first-in-class or best-in-class treatments, Edgewise Therapeutics strategically positions itself to create significant value for its patients and stakeholders alike.
